Innate Pharma Statistics

Total Valuation

Innate Pharma has a market cap or net worth of $127.25 million. The enterprise value is $113.48 million.

Market Cap	127.25M
Enterprise Value	113.48M

Important Dates

The last earnings date was Thursday, March 26, 2026, before market open.

Earnings Date	Mar 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Innate Pharma has 93.79 million shares outstanding. The number of shares has increased by 10.54% in one year.

Current Share Class	n/a
Shares Outstanding	93.79M
Shares Change (YoY)	+10.54%
Shares Change (QoQ)	+6.11%
Owned by Insiders (%)	0.74%
Owned by Institutions (%)	1.61%
Float	65.94M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	12.04
Forward PS	8.64
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	10.73
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.27

Current Ratio	1.27
Quick Ratio	1.14
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-122.75

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-38.85%
Return on Invested Capital (ROIC)	-165.88%
Return on Capital Employed (ROCE)	-207.17%
Weighted Average Cost of Capital (WACC)	7.17%
Revenue Per Employee	$60,764
Profits Per Employee	-$331,838
Employee Count	174
Asset Turnover	0.10
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.80% in the last 52 weeks. The beta is 0.75, so Innate Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.75
52-Week Price Change	-29.80%
50-Day Moving Average	1.49
200-Day Moving Average	1.83
Relative Strength Index (RSI)	44.69
Average Volume (20 Days)	26,200

Short Selling Information

The latest short interest is 64,220, so 0.07% of the outstanding shares have been sold short.

Short Interest	64,220
Short Previous Month	71,264
Short % of Shares Out	0.07%
Short % of Float	n/a
Short Ratio (days to cover)	2.30

Income Statement

In the last 12 months, Innate Pharma had revenue of $10.57 million and -$57.74 million in losses. Loss per share was -$0.65.

Revenue	10.57M
Gross Profit	-40.64M
Operating Income	-63.41M
Pretax Income	-57.74M
Net Income	-57.74M
EBITDA	-62.59M
EBIT	-63.41M
Loss Per Share	-$0.65

Full Income Statement

Balance Sheet

The company has $40.28 million in cash and $26.50 million in debt, giving a net cash position of $13.78 million or $0.15 per share.

Cash & Cash Equivalents	40.28M
Total Debt	26.50M
Net Cash	13.78M
Net Cash Per Share	$0.15
Equity (Book Value)	-25.48M
Book Value Per Share	-0.27
Working Capital	11.81M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$61.94 million and capital expenditures -$164,377, giving a free cash flow of -$61.89 million.

Operating Cash Flow	-61.94M
Capital Expenditures	-164,377
Depreciation & Amortization	819,059
Net Borrowing	-10.43M
Free Cash Flow	-61.89M
FCF Per Share	-$0.66

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-599.77%
Pretax Margin	-546.11%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Innate Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.54%
Shareholder Yield	-10.54%
Earnings Yield	-45.38%
FCF Yield	-48.64%

Analyst Forecast

The average price target for Innate Pharma is $5.75, which is 310.71% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$5.75
Price Target Difference	310.71%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	62.00%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Innate Pharma has an Altman Z-Score of -11.09 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-11.09
Piotroski F-Score	1